8-K: Zomedica Corp. Announces Transition to OTCQB Market Following NYSE American Delisting

Zomedica Corp. will transition to the OTCQB Venture Market after being delisted from the NYSE American due to noncompliance with listing standards regarding low share price.

Summary

• Zomedica Corp. has been notified by the NYSE American that its common shares will be delisted due to noncompliance with Section 1003(f)(v) of the NYSE American Company Guide, which relates to the company's common shares trading at a low price.
• Trading in Zomedica's common shares on the NYSE American was suspended as of March 4, 2025.
• The NYSE American will apply to the SEC to delist the company's common shares.
• Zomedica has received approval to have its common shares quoted on the OTCQB Market under the ticker symbol ZOMDF, with trading expected to commence on March 5, 2025.
• The company states that the transition to the OTCQB Market will not affect its business or operations.
• Zomedica will continue to file periodic reports with the SEC.
• Zomedica is a veterinary health company offering point-of-care diagnostic and therapeutic products.
• Zomedica's total addressable market in the U.S. exceeds $2 billion.
• Zomedica employs approximately 150 people and manufactures and distributes its products from its facilities in Georgia and Minnesota.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the delisting from the NYSE American, which raises concerns about the company's financial health and investor confidence. However, the company's efforts to transition to the OTCQB Market and its continued focus on growth provide some positive counterpoints.

Positives

• Zomedica has secured approval to trade on the OTCQB Market, ensuring continued trading of its shares.
• The company maintains that the transition will not affect its business operations.
• Zomedica will continue to file periodic reports with the SEC, ensuring transparency for investors.
• Zomedica's CEO emphasizes the company's dedication to delivering value to shareholders and the veterinary community.
• Zomedica's total addressable market in the U.S. exceeds $2 billion.

Negatives

• Zomedica's delisting from the NYSE American is a negative event, indicating a failure to meet listing requirements.
• The delisting was triggered by a sustained low share price, reflecting investor concerns or company performance issues.

Risks

• The company faces the risk of reduced visibility and liquidity associated with trading on the OTCQB Market compared to the NYSE American.
• The company's future results are subject to market conditions, regulatory approvals, and competitive developments.
• The company's share price may be negatively impacted by the delisting.

Future Outlook

Zomedica anticipates a smooth transition to the OTCQB Market and remains focused on driving growth and advancing its pipeline of veterinary products. The company will continue to file periodic reports with the SEC and comply with applicable regulatory requirements.

Management Comments

• Larry Heaton, Chief Executive Officer of Zomedica, stated that the company is disappointed by the delisting but believes the transition to the OTCQB Market will allow Zomedica to maintain strong engagement with investors while focusing on growth and product development.
• Heaton emphasized that the value of the company's assets and opportunities for growth remain the same despite the change in trading venue.

Industry Context

The announcement reflects the challenges faced by smaller companies in maintaining listing compliance on major exchanges. The move to the OTCQB is a common path for companies seeking to maintain trading liquidity while addressing compliance issues. Zomedica operates in the growing veterinary health market, which is driven by increasing pet ownership and spending on animal care.

Comparison to Industry Standards

• Many smaller cap companies in the animal health sector, such as PetMed Express and IDEXX Laboratories, maintain listings on major exchanges like NASDAQ and NYSE, indicating Zomedica's situation is not the industry norm.
• Companies like VCA Antech (now part of Mars, Inc.) have demonstrated the potential for significant growth and acquisition in the veterinary services and diagnostics market, setting a high benchmark for Zomedica's future aspirations.
• The transition to OTCQB is often seen as a step down, and companies like Zomedica will need to demonstrate strong performance to regain investor confidence and potentially relist on a major exchange in the future.

Stakeholder Impact

• Shareholders may experience reduced liquidity and potential price volatility due to the transition to the OTCQB Market.
• Employees may face uncertainty regarding the company's future prospects.
• Customers and suppliers are unlikely to be directly impacted by the change in trading venue.

Next Steps

• Commence trading on the OTCQB Market under the ticker symbol ZOMDF on March 5, 2025.
• Continue filing periodic reports with the SEC.
• Focus on driving growth and advancing the pipeline of veterinary products.

Key Dates

Keywords

Zomedica, OTCQB, NYSE American, delisting, veterinary health, ZOMDF, common shares, trading, SEC, animal health